The QualityStocks Daily Tuesday, September 24th, 2024

Today's Top 3 Investment Newsletters

360 Wall Street(MSS) $1.5900 +122.38%

QualityStocks(SEEL) $0.2990 +57.37%

MarketClub Analysis(CAPR) $9.1000 +52.43%

The QualityStocks Daily Stock List

Seelos Therapeutics (SEEL)

QualityStocks, MarketBeat, StockEarnings, StockMarketWatch, PsychedelicNewsWire, MarketClub Analysis, TradersPro, Schaeffer's, Prism MarketView, BUYINS.NET, Trades Of The Day, The Online Investor, Premium Stock Alerts, INO Market Report and 360 Wall Street reported earlier on Seelos Therapeutics (SEEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Seelos Therapeutics Inc. (NASDAQ: SEEL) (FRA: NXEN) is a clinical-stage biopharmaceutical firm that is engaged in the development and commercialization of new technologies and treatments for respiratory disorders, central nervous system disorders as well as major depressive and post-traumatic stress disorders.

Seelos Therapeutics Inc. is based in New York and was incorporated in 2016. The firm serves patients in the United States and its portfolio is made up of late-stage clinical assets that target various movement and psychiatric disorders.

Seelos Therapeutics Inc.’s lead product candidates include intranasal ketamine indicated for the treatment of acute suicidal behavior and ideation in patients with post-traumatic stress disorder and major depressive disorder known as SLS-002; a protein stabilizer indicated for the treatment of Sanfilippo syndrome, SLS-005; a partial dopamine agonist indicated for the treatment of Parkinson’s disease dubbed SLS-006. Other preclinical programs include an injectable post-op pain management therapy named SLS-012; an oral histamine antagonist for narcolepsy and associated disorders, SLS-010; another treatment for Parkinson’s disease, SLS-004; an oral antagonist indicated for the treatment of chronic inflammation in pediatric orphan indications and asthma, SLS-008 and an inhibitor developed to help treat Parkinson’s disease patients dubbed SLS-007.

Seelos Therapeutics Inc.’s SLS-002 candidate has shown great potential in helping manage acute-suicidal-ideation-behavior for PTSD and major depressive disorder, which has no approved medications at the moment. The likelihood of the candidate being approved by the FDA after successful completion of its clinical trial is high. Mental health conditions have been on the rise and with the pandemic’s mental health effects not fully known, the drug may address a lot of the unmet medical needs that current medications on the market do not.

Seelos Therapeutics (SEEL), closed Tuesday's trading session at $0.299, up 57.3684%, on 335,516,676 volume. The average volume for the last 3 months is 903,292 and the stock's 52-week low/high is $0.1815/$53.04.

Capricor Therapeutics (CAPR)

StockMarketWatch, MarketClub Analysis, MarketBeat, QualityStocks, BUYINS.NET, TraderPower, TradersPro, StreetInsider, Prism MarketView, Schaeffer's, Wall Street Resources, Buzz Stocks, HotOTC, Penny Pick Finders, Marketbeat.com, OTCtipReporter, Jason Bond, PennyStockProphet, PennyStockScholar, AllPennyStocks, Profitable Trader Authority, smartOTC, StockOodles, Streetwise Reports, The Street, Wall Street Mover and PoliticsAndMyPortfolio reported earlier on Capricor Therapeutics (CAPR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Capricor Therapeutics Inc. (NASDAQ: CAPR) (FRA: 4LN2) is a clinical stage biotechnology firm that is engaged in developing transformative exosome and cell-based therapies for preventing and treating various rare ailments, like duchenne muscular dystrophy.

The firm has its headquarters in Beverly Hills, California and was incorporated in 2005. It operates in the healthcare sector, under the biotech and pharma sub-industry and serves consumers in Canada and the U.S.

The company is well positioned at the forefront of one of the biggest segments of the healthcare sectors in the US- cardiovascular disease, given that it’s a developer of innovative treatments. It is party to a collaboration agreement with Lonza Houston Inc. which entails developing its cell therapy candidate dubbed CAP-1002, indicated for treating duchenne muscular dystrophy as well as other ailments.

The enterprise’s product pipeline is made up of a formulation currently in pre-clinical development dubbed CAP-2003, indicated for treating trauma-related conditions and injuries and an allogeneic cardiac-derive treatment dubbed CAP-1002, which is indicated for treating cardiac conditions like post myocardial infarction with cardiac dysfunction and heart failure and is also currently in phase 2 clinical trials testing its effectiveness in treating cytokine storms linked to the coronavirus. This formulation also concluded phase 2 clinical trials testing its effectiveness in treating late stage Duchenne muscular dystrophy. In addition to this, the company is involved in developing 2 vaccine candidates for the potential prevention of the coronavirus, which are currently in the preclinical stage.

The firm’s CAP-1002 has shown tremendous potential in the management of Duchenne muscular dystrophy, which occurs in 1 in every 3600 live male births and affects about 200,000 young men and boys across the globe. The treatment’s success would not only address patients’ needs for a disease that has no cure but also bring in significant investments into the firm, which would enhance growth.

Capricor Therapeutics (CAPR), closed Tuesday's trading session at $9.1, up 52.4288%, on 30,528,283 volume. The average volume for the last 3 months is 4,076 and the stock's 52-week low/high is $2.68/$9.2449.

Four Seasons Education (FEDU)

QualityStocks, Trading Concepts and StockMarketWatch reported earlier on Four Seasons Education (FEDU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Four Seasons Education (Cayman) Inc. (NYSE: FEDU) is an education firm that is engaged in the provision of after-school education services with a focus on high-quality elementary school mathematics education.

The firm has its headquarters in Shanghai, the People’s Republic of China and was incorporated in 2007 by Peiqing Tian. It operates as part of the education sector and serves consumers in China.

The company helps unlock every student’s intellectual potential through the use of education that can benefit the student’s life, career and academic prospects. Its courses are divided into kindergarten, middle school and elementary school programs.

The enterprise’s education services are made up of experimental courses for middle school English, Chinese, chemistry, physics, mathematics and other subjects; study trips to historical scenic spots and sites; interest-oriented programs which include courses delivered to K-12 learning institutions and workshops on some mathematics topics; and picture talk workshops which allow students to develop their cognitive abilities. In addition to this, it offers courses on the Chinese phonetic system, namely pinyin, which students learn when they start the formal study of Chinese. Furthermore, the enterprise also offers management and education consulting services, as well as online education services through its mobile application and website.

Four Seasons Education (FEDU), closed Tuesday's trading session at $11.55, up 15.3846%, on 15,732 volume. The average volume for the last 3 months is 161,874 and the stock's 52-week low/high is $7.145158/$22.70.

Sitka Gold (SITKF)

We reported earlier on Sitka Gold (SITKF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sitka Gold Corp (OTCQB: SITKF) (CNSX: SIG) (FRA: 1RF) is a mineral exploration firm focused on exploring for minerals at resource properties in the U.S. and Canada.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2015, on January 13th. It operates as part of the gold industry, under the basic materials sector. The firm serves consumers around the globe.

The company explores for gold, zinc, silver, and copper deposits. It owns interests in the OGI property, which comprises of 99 quartz mining claims located in Dawson City, Yukon; the Coppermine River project, which covers an area of about 50,000 hectares and is located in Nunavut; the RC Gold property, which comprises of 1,891 claims that cover an area of approximately 37,600 hectares situated in Yukon; and the Alpha Gold property, which includes 293 claims that covers an area of approximately 4780 acres situated in Eureka County, Nevada. The company also holds an option to acquire a 100% interest in the Burro Creek property, which covers an area of about 750 hectares. This property includes 4 patented mineral claims and 35 surrounding lode mineral claims located in the Mohave County, Arizona. It also holds an option to acquire interest in the Barney Ridge property situated to the east of Dawson City, Yukon. In addition to this, it holds a 100% interest in the Mahtin property, which comprises 1,447 quartz mining claims that cover an area of 30,242 hectares located in Yukon territory; and the Clear Creek Gold property, located to the east of Dawson City, Yukon.

Sitka Gold (SITKF), closed Tuesday's trading session at $0.2432, up 15.2061%, on 522,105 volume. The average volume for the last 3 months is 9.58M and the stock's 52-week low/high is $0.0901/$0.24365.

Cipher Mining (CIFR)

Schaeffer's, MarketClub Analysis, MarketBeat, StockEarnings, TradersPro, QualityStocks, Inside Trading, The Online Investor, smartmoneytrading, Money Wealth Matters, INO Market Report and Early Bird reported earlier on Cipher Mining (CIFR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cipher Mining Inc. (NASDAQ: CIFR) is a Bitcoin mining firm that is engaged in developing and operating cryptocurrency mining businesses.

The firm has its headquarters in Rye, New York and was incorporated in 2021. Prior to its name change, the firm was known as Good Works Acquisition Corp. It operates as part of the financial activities industry. The firm serves consumers around the globe.

The company’s objective is to be the leading mining firm for Bitcoin in the U.S. through its dedicated and seasoned senior management team. Its mission is to offer the important foundation needed for the Bitcoin network to flourish. The company intends to do so through market-leading power purchase arrangements and the use of the best-in-class technology, which will enable it to become a market leader in cryptocurrency mining.

The enterprise is focused on strengthening and expanding the critical infrastructure of Bitcoin’s network in the United States. It offers financial services, which include Bitcoin mining services.

The company, which has entered into a number of low-cost power purchase agreements as well as machine contracts for about 142,000 Bitcoin mining rigs which can generate a hash rate of up to 19.5 EH/s, plans to strengthen its Bitcoin critical network infrastructure by building out a significant Bitcoin mining footprint in the U.S. This footprint will help market the company and its services, which will bring in more investments into the company and grow its reach. This will in turn grow its revenues and boost its growth, which will benefit its stakeholders.

Cipher Mining (CIFR), closed Tuesday's trading session at $3.44, up 15.0502%, on 22,433,131 volume. The average volume for the last 3 months is 9.84M and the stock's 52-week low/high is $2.155/$7.99.

iQIYI Inc. (IQ)

Schaeffer's, MarketClub Analysis, StockEarnings, MarketBeat, StocksEarning, InvestorPlace, The Street, INO Market Report, StreetInsider, Trades Of The Day, QualityStocks, Kiplinger Today, Wealth Insider Alert, Top Pros' Top Picks, FreeRealTime, The Online Investor, Zacks, TradersPro, Daily Trade Alert, InvestmentHouse, Cabot Wealth, Investing Daily, AllPennyStocks, Earnings360, BUYINS.NET, MarketClub, Market Intelligence Center Alert, TradeSmith Daily, StockMarketWatch and Kiplinger’s Weekly Update reported earlier on iQIYI Inc. (IQ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

iQIYI Inc. (NASDAQ: IQ) (FRA: IQ8) is an online entertainment service provider that is engaged in the provision of online entertainment services under its own brand.

The firm has its headquarters in Beijing, the People’s Republic of China and was incorporated in November 2009 by Yu Gong. Prior to its name change in November 2017, the firm was known as Qiyi.com Inc. The firm has forty-nine companies in its corporate family and serves consumers across the globe, with a focus on China.

The company produces original video content and distributes appealing user-generated content, partner-generated content and professionally-produced content. Its revenue is generated from online advertising services and membership services. The company generates most of its revenue from China. It operates as a subsidiary of Baidu Holdings Ltd.

The enterprise provides different services and products which include e-commerce, animations, online literature, live broadcasting, online games, internet video and social media platform. It operates a platform which offers a collection of internet video content. This is in addition to operating an e-commerce platform dubbed iQIYI Mall, which centers on entertainment-related merchandise like VR glasses. It also sells beauty and skincare products, apparel and accessories and electronics. The enterprise also offers a social platform known as iQIYI Paopao; and a live broadcasting service dubbed iQIYI Show, which allows users to follow their favorite shows, celebrities and hosts in real time via live broadcasting.

The firm recently announced its latest financial results for 2021 which show increases in its revenues. Its CEO noted that they were focused on executing its diversified content strategy and improving the efficiency of its operations.

iQIYI Inc. (IQ), closed Tuesday's trading session at $2.44, up 14.0187%, on 28,165,756 volume. The average volume for the last 3 months is 118,842 and the stock's 52-week low/high is $1.92/$5.80.

Flexpoint Sensor Systems (FLXT)

QualityStocks, FeedBlitz, SmallCapVoice, Goldman Small Cap Research, Greenbackers, HEROSTOCKS, Stock Brain, PennyStocks24, PoliticsAndMyPortfolio, Buzz Stocks, HotOTC, M2 Communications, Penny Pick Finders, Penny Stocks Profile, PennyStockProphet, BullRally, PlanetPennies, Wallstreetlivechat, Pumps and Dumps, SecretStockPromo, Stock Rich, Stockhunter.us, StockMister, StockOnion, TheStockWizards.net, Wall Street Mover and PennyTrader Publisher reported earlier on Flexpoint Sensor Systems (FLXT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Flexpoint Sensor Systems Inc. (OTC: FLXT) is a company focused on designing, manufacturing, and selling bend sensor technology and products using its patented Bend Sensor flexible potentiometer technology.

The firm has its headquarters in West Jordan, Utah and was incorporated in 1995. Prior to its name change in July 1999, the firm was known as Micropoint Inc. It operates as part of the scientific and technical instruments industry, under the technology sector. The firm serves consumers in the United States.

The enterprise’s Bend Sensor technology is a flexible potentiometer bend sensor product consisting of a coated substrate, such as plastic that changes electrical conductivity as it is bent in a consistent manner. It offers automotive products; glove systems for medical, gaming, and virtual reality segments, as well as health rehabilitation, unmanned systems control, smartphone interaction, and professional training applications; swell sensors; and monitoring systems. The enterprise also provides products flow control applications; and other applications that include industrial control systems, medical equipment and instrumentation, computer peripherals, automotive transmission equipment, commercial vending equipment, and other devices. It operates primarily from an 8,000 ft2 facility in Utah, just southwest of Salt Lake City. The enterprise sells directly and through other channels globally under agreements with a multitude of partners and distributor.

Flexpoint Sensor Systems, which recently announced its latest financial results, continues to concentrate its marketing resources on a limited number of customers that have the greatest potential to generate the most short-term revenue while still building relationships with its larger customers.

Flexpoint Sensor Systems (FLXT), closed Tuesday's trading session at $0.0048, off by 2.0408%, on 233,906 volume. The average volume for the last 3 months is 25.343M and the stock's 52-week low/high is $0.0007/$0.0116.

Alphabet (GOOGL)

The Street, InvestorPlace, Kiplinger Today, Zacks, The Online Investor, Schaeffer's, Daily Trade Alert, Investopedia, Trades Of The Day, Market Intelligence Center Alert, Money Morning, Early Bird, MarketBeat, MarketClub Analysis, StreetInsider, Uncommon Wisdom, StreetAuthority Daily, Top Pros' Top Picks, Wealth Insider Alert, Daily Profit, StrategicTechInvestor, Wyatt Investment Research, The Street Report, Wall Street Daily, The Wealth Report, TopStockAnalysts, Money and Markets, CustomerService, Louis Navellier, AllPennyStocks, MarketWatch, StocksEarning, All about trends, Investing Daily, Daily Wealth, TipRanks, ProfitableTrading, Stansberry Research, CNBC Breaking News, INO.com Market Report, Marketbeat.com, Investors Alley, INO Market Report, QualityStocks, MarketTamer, MarketArmor.com, Market Intelligence Center, Darwin Investing Network, Trading Tips, Power Profit Trades, InvestorGuide, Stock Up Featured, InsiderTrades, Options Elite, Barchart, InvestorIntel, DividendStocks, Money Wealth Matters, Cabot Wealth, Total Wealth, The Night Owl, StockEarnings, SmallCapNetwork, Daily Dividends, GorillaTrades, TheOptionSpecialist, WStreet Market Commentary, FreeRealTime, The Daily Market Alert, Insider Wealth Alert, Jon Markman’s Pivotal Point, Dynamic Wealth Report, Investiv, Investing Futures, Trader Prep, The Weekly Options Trader, Investing Signal, Investor Guide, InvestorsObserver Team, Eagle Financial Publications, SmallCap Network, Short Term Wealth, Smartmoneytrading, StockMarketWatch, The Motley Fool, Trading Concepts, Chaikin PowerFeed, Average Joe Options, Market Authority, Trade of the Week, 24/7 Trader, Investing Lab, Jim Cramer, Wealth Daily, TradingPub, Equities.com, The Wall Street Transcript, Investment House, Shah's Insights & Indictments, Financials Trends, Inside Investing Daily, Investing Breakout, Investment U, Earnings360 Newsletter, Stock Barometer, TrendAdvisor, Tradespoon, TradeSmith Daily, Traders For Cash Flow, Top Pros Top Picks, The Trading Report, The Stock Dork, RedChip, BUYINS.NET, ChartAdvisor, Profit Confidential, Lance Ippolito, Mind Over Markets, StockReport, Pennystockmania, CNBC, Contrarian Outlook, Schaeffer’s, bullseyeoptiontrading, BillionDollarClub, Beat The Street, empirefinancialresearch, Earnings360, 360 Wall Street, Day Trade Alert, Candle Stick Forum, Energy and Capital, Economic News Room, Dividend Opportunities, Energy & Resources Digest, StreetAuthority Financial, Rockwell Trading, Roundtable Roundup, SECFilings.com News, SmallCapVoice, Smart Investing Today, Smart Money Press, SmartTrading, Microcapmillionaires, Street Insider, PoliticsAndMyPortfolio.com, Summa Money, SwingTradeOnline, SystemTrading, Technology Profits Daily, Tim Bohen, Tim Sykes, wyatt research newsletter, Stock Gumshoe, Liberty Through Wealth, Greenbackers, HotStockProfits, iDigital Market and Inside Trading reported earlier on Alphabet (GOOGL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Alphabet (NASDAQ: GOOGL, GOOG), through its subsidiary Google, has embarked on an innovative partnership with Volkswagen to integrate an artificial intelligence (“AI”) assistant into Volkswagen vehicles. This collaboration is a strategic move by Google to penetrate deeper into the automotive industry, leveraging its advanced AI and cloud computing technologies. The AI assistant is designed to enhance the driving experience by providing vehicle-related information and assistance through a user-friendly smartphone app. This initiative is part of Google’s broader ambition to expand its footprint in the enterprise AI application sector, showcasing its commitment to leveraging technology to solve real-world problems.

The technical prowess behind the AI assistant, as highlighted by Google Cloud CEO Thomas Kurian, underscores the complexity and innovation driving this project. By employing Google’s Gemini large language models and cloud computing capabilities, the AI assistant offers multimodal data processing, enabling it to understand and respond to a wide range of user queries. This capability extends beyond mere speech recognition, allowing users to interact with the assistant in various ways, such as pointing their phone cameras at dashboard symbols for explanations. Initially available to owners of Volkswagen’s Atlas and Atlas Cross Sport models, the plan is to expand this service to more models, indicating a scalable approach to integrating AI in vehicles.

Financially, Alphabet Inc. stands strong with a price-to-earnings (“P/E”) ratio of 22.93, reflecting investor confidence in its profitability and growth prospects. The company’s price-to-sales (“P/S”) and enterprise value to sales (“EV/Sales”) ratios, both at approximately 6.13, demonstrate a healthy valuation by the market, acknowledging Alphabet’s significant sales volume and its strategic positioning within the tech industry. Furthermore, the enterprise value to operating cash flow (“EV/OCF”) ratio of 19.15 highlights Alphabet’s efficient cash generation capabilities, a critical factor for sustaining its ambitious projects and investments in AI and cloud computing.

Alphabet’s financial health is further evidenced by its low debt-to-equity (“D/E”) ratio of 0.049, indicating a minimal reliance on debt financing and a strong equity base. This financial stability is crucial for supporting large-scale projects like the partnership with Volkswagen. Additionally, with a current ratio of over 2.08, Alphabet exhibits a robust ability to meet its short-term obligations, ensuring operational resilience and flexibility. This financial foundation not only supports Alphabet’s current ventures but also positions it well for future growth opportunities in the cloud computing market and beyond.

As Alphabet seeks to enhance its standing in the competitive cloud computing market, currently trailing behind giants like Amazon and Microsoft, this partnership with Volkswagen represents a strategic move to diversify its revenue streams and solidify its presence in the automotive sector. With cloud computing contributing $33 billion to its $307 billion total revenue in 2023, and AI solutions generating significant revenue, Alphabet’s financial metrics and strategic partnerships reflect a company on a robust growth trajectory, leveraging technology to expand its market reach and enhance user experiences across industries.

To view the company’s latest earnings release, visit https://ibn.fm/1vFFk

About Alphabet Inc.

Alphabet is a collection of companies, the largest of which is Google. Larry Page and Sergey Brin founded Google in September 1998 and the company is headquartered in Mountain View, California. Billions of people use its wide range of popular products and platforms each day, like Search, Ads, Chrome, Cloud, YouTube and Android. For more information, visit the company’s website at www.ABC.xyz.

Alphabet (GOOGL), closed Tuesday's trading session at $162.29, up 0.2718567%, on 23,332,147 volume. The average volume for the last 3 months is 1.108M and the stock's 52-week low/high is $120.2057/$191.75.

Mind Medicine Inc. (MNMD)

QualityStocks, InvestorPlace, Schaeffer's, PsychedelicNewsWire, MarketBeat, TradersPro, The Wealth Report, The Street, The Stock Dork, MarketClub Analysis, Daily Trade Alert, Wealth Daily and Trades Of The Day reported earlier on Mind Medicine Inc. (MNMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Microdosing is the practice of consuming low doses of psychedelic substances such as psilocybin mushrooms or LSD. This allows an individual to gain the benefits of the drugs without experiencing any psychoactive effects.

Peggy Van de Plassche, a microdosing expert and author, recently discussed the benefits of microdosing and the stigma surrounding psychedelics on the Future of Work podcast.

Van de Plassche’s personal journey with psychedelics, which started as a quest to improve her mental health, greatly influenced her current path. Her experience with psychedelics caused significant positive changes in her mental well-being, leading her to advocate for psychedelics integration into the healthcare and wellness systems.

According to Van de Plassche, microdosing could help improve depressive and anxiety symptoms as well as build resilience against stress, which positively impacts an individual’s quality of life and overall productivity. Microdosing also calms an individual’s nervous system, alleviating their mental burden and enhancing mood stability and overall mood.

The practice may also improve workplace wellness by improving the connection one has to themselves and others. Improved communication skills and increased empathy may also contribute to better relationships in the workplace and more mindful leadership. In addition to this, microdosing may boost an individual’s performance by increasing creativity, attention and focus. This makes individuals more effective problem-solvers and collaborators.

While evidence has shown that psychedelics may be beneficial in the treatment of various mental-health disorders, there still exists stigma rooted in the misconceptions that came up in the 1970s. At the time, psychedelics were linked to negative stories.

This stigma still rears its head today, even though more individuals are exploring the drugs’ benefits. Education is needed to overcome these outdated stigmas. By encouraging open conversations and sharing credible information, public perception of these drugs can shift and pave the way for the acceptance and use of psychedelics.

With more than 970 million individuals in the world living with a mental disorder, prioritizing the well-being and mental health of employees is equally important.

Companies may benefit from microdosing because their workforces will be better connected, more focused and less stressed. Improved mental health also correlates directly with improved productivity, increased job satisfaction and reduced rates of burnout.

This doesn’t mean that getting microdosing accepted in the workplace will be an easy feat. The fragmented legal landscape in the United States where legislation on psychedelics varies by state, country, city and federal jurisdictions doesn’t help either.

At the moment, however, enterprises focusing on developing psychedelic medicines, such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), are looking to the clinical use of these treatments with a prescription from a qualified medical practitioner. Microdosing, which is self-prescribed, is still off the table for these businesses.

Mind Medicine Inc. (MNMD), closed Tuesday's trading session at $6.06, up 3.2368%, on 729,811 volume. The average volume for the last 3 months is 1.324M and the stock's 52-week low/high is $2.41/$12.22.

Aurora Cannabis Corp. (ACB)

InvestorPlace, Schaeffer's, StocksEarning, MarketClub Analysis, MarketBeat, The Street, QualityStocks, StockEarnings, Trades Of The Day, Daily Trade Alert, StreetInsider, The Online Investor, Wealth Insider Alert, Market Intelligence Center Alert, Kiplinger Today, StockMarketWatch, CFN Media Group, Investopedia, CannabisNewsWire, Stock Up Featured, Profit Trends, BUYINS.NET, Early Bird, BlackSwanAlert, The Rich Investor, StreetAuthority Daily, Jim Cramer, TheoTrade, Cannabis Financial Network News, CNBC Breaking News, Inside Trading, Daily Profit, Investors Alley, Investors Underground, Market Intelligence Center, Outsider Club, Zacks, Technology Profits Daily, The Wealth Report, TheTradingReport, Top Pros' Top Picks, Tradespoon, Wall Street Window and Money and Markets reported earlier on Aurora Cannabis Corp. (ACB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Last month, Ohio kicked off its recreational cannabis sales, raising questions about how this would impact Michigan’s already thriving industry, which attracts many Ohio customers. Michigan had become a popular destination for Ohio residents seeking cannabis, with many dispensaries conveniently located near the state border in cities such as Morenci and Monroe.

Ohio’s dispensaries sold close to $55 million worth of product in the first month of the state’s legal cannabis sales, which got underway in August.

Despite this, the Michigan Marijuana Regulatory Agency has released new data indicating that the state’s dispensaries have not suffered. In actuality, sales kept rising: recreational marijuana sales at Michigan dispensaries reached $294 million in August, up 3% from July’s $286 million. Sales increased significantly from $271 million even in August of the previous year, indicating a 9% growth overall.

A closer look at sales figures from regions bordering Ohio shows a similar trend of increased sales. In southwest Michigan, recreational sales reached $86 million in August, up from July’s $82 million. Likewise, the southeast and east regions of Michigan saw sales grow from $121 million to $123 million.

These increases indicate that Ohio’s entry into the recreational market has not slowed down Michigan’s cannabis industry, particularly in border regions.

However, not everyone in Michigan is seeing that same trend. Sean Lyden, CEO of Green Labs Provisions, a dispensary located in Luna Pier, which is six miles from Ohio’s border, reported a 15% drop in sales during August compared to the previous month. Despite this decline, Lyden remains cautiously optimistic, believing that the most significant challenges may have already passed.

One factor that still draws Ohio customers to Michigan is the price difference between the two states. In Ohio, the cost of an ounce of marijuana flower is around $250, while in Michigan, the same amount was priced at around $80 in August.

Michigan’s cannabis market, now almost five years old, has experienced a substantial drop in prices due to increased competition and supply. For the time being, Ohio’s higher prices and limited number of dispensaries may continue to encourage Ohio residents to cross state lines to purchase marijuana in Michigan, where competition is fiercer and prices are lower.

However, Lyden anticipates that as Ohio’s market grows and becomes more competitive, the situation may change. To stay ahead of potential market shifts, he is considering expanding his business with additional dispensaries in Michigan and possibly in Ohio. This expansion could help his company become less dependent on Ohio customers visiting the Luna Pier location.

The growing sales in these two states are helping to strengthen the reach of the industry, and enterprises in other jurisdictions, such as Aurora Cannabis Corp. (NASDAQ: ACB) (TSX: ACB), will be hoping that the momentum keeps building in those new markets.

Aurora Cannabis Corp. (ACB), closed Tuesday's trading session at $5.74, up 2.3173%, on 514,493 volume. The average volume for the last 3 months is 3.655M and the stock's 52-week low/high is $2.84/$9.35.

WiSA Technologies (WISA)

QualityStocks, SmallCapRelations, TechMediaWire, MissionIR, Stocks to Buy Now, InvestorBrandNetwork, SeriousTraders, AwesomeStocks, StockMarketWatch, MarketClub Analysis, MarketBeat, StockEarnings, StreetInsider, Small Caps, 360 Wall Street, PennyStockProphet, BUYINS.NET, Penny Stock 101, StockRockandRoll, Premium Stock Alerts, Profitable Trader Authority, PennyStockLocks, Schaeffer's, Awareness Stocks, StockWireNews, Buzz Stocks, Fierce Analyst, HotOTC, PennyStockScholar, Jeff Bishop, Money Wealth Matters, OTCtipReporter, Penny Pick Finders, The Stock Dork and StockOnion reported earlier on WiSA Technologies (WISA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

WiSA Technologies (NASDAQ: WISA) has announced that Data Vault Holdings Inc., which is under a definitive asset purchase agreement to sell its Datavault(R)and ADIO(R) intellectual property (“IP”) and information technology (“IT”) assets to WiSA, has launched a platform designed to provide secure, real-time, blockchain-based academic credential verification: VerifyU. Datavault collaborated with Arizona State University (“ASU”) and the university’s Luminosity Lab in the development of the platform.

VerifyU offers a key solution for students, educational institutions and employers who are looking for both credible and efficient methods to confirm academic verifications. According to the announcement, Datavault anticipates licensing its VerifyU platform to 20 to 30 educational institutions next year.

“By harnessing cutting-edge technologies like blockchain and AI, VerifyU addresses both the needs of students and the requirements of employers and academic institutions,” said Datavault CEO Nathanial Bradley in the press release. “Our platform ensures academic qualifications are verified quickly and securely, giving students the tools they need to showcase their achievements with confidence. VerifyU has the potential to significantly lower universities’ administrative costs as well as drive revenue to the university, and our goal is license VerifyU to 20 to 30 educational institutions in 2025.”

To view the full press release, visit https://ibn.fm/wHLKa

About WiSA Technologies Inc.

WiSA Technologies is a leading provider of immersive, wireless sound technology for intelligent devices and next-generation home entertainment systems. Working with leading CE brands and manufacturers such as Harman International, a division of Samsung; LG; Hisense; TCL; Bang & Olufsen; Platin Audio; and others, the company delivers immersive wireless sound experiences for high-definition content, including movies and video, music, sports, gaming/esports and more. WiSA is a founding member of the Wireless Speaker and Audio Association (“WiSA”[TM]) whose mission is to define wireless audio interoperability standards as well as work with leading consumer electronics companies, technology providers, retailers and ecosystem partners to evangelize and market spatial audio technologies driven by WiSA Technologies. The company is headquartered in Beaverton, Oregon, with sales teams in Taiwan, China, Japan, Korea and California. For more information about the company, please visit www.WiSATechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to WISA are available in the company’s newsroom at https://ibn.fm/WISA

WiSA Technologies (WISA), closed Tuesday's trading session at $1.96, up 15.9763%, on 1,846,589 volume. The average volume for the last 3 months is 9,444 and the stock's 52-week low/high is $1.15/$96.69.

Foremost Lithium Resource & Technology Ltd. (FMST)

StockWireNews, Small Cap Firm, Fierce Analyst, QualityStocks, Jeff Bishop and Broad Street reported earlier on Foremost Lithium Resource & Technology Ltd. (FMST), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Foremost Lithium (NASDAQ: FMST) (CSE: FAT), a North American hard-rock lithium exploration company, has entered a property acquisition agreement with Denison Mines Corp. According to the agreement, Denison has granted Foremost an option to acquire up to 70% of Denison’s interest in 10 highly prospective uranium exploration properties, which cover some 330,000 acres in the Athabasca Basin; the agreement also contains other ancillary agreements. In addition, Foremost Lithium announced that it plans to change its name to Foremost Clean Energy Ltd. and that Denison CEO and president David Cates will join the company’s board of directors.

“We are pleased to announce a transformative transaction with Denison, a clear leader in the uranium sector,” said Foremost president and CEO Jason Barnard in the press release. “Uranium prices have seen significant strength in recent years driven by the global demand for clean energy, which has been reinforced by supportive government policies and geopolitical events underscoring the need for reliable western uranium supply. The Athabasca Basin is recognized as one of the world’s leading uranium jurisdictions, with numerous producing mines and high-profile development projects. This collaboration will advance significant near-term exploration and development efforts across numerous high-quality exploration projects to maximize the properties’ potential for the benefit of both Foremost and Denison shareholders.”

To view the full press release, visit https://ibn.fm/yWPo8

About Foremost Lithium Resource & Technology Ltd.

Foremost Lithium, assuming the effectiveness of the transaction, will be an emerging North American uranium exploration company with interests in 10 prospective properties spanning over 330,000 acres in the prolific, uranium-rich Athabasca Basin. As global demand for decarbonization accelerates, the need for nuclear power is crucial. Foremost expects to be positioned to capitalize on the growing demand for uranium through discovery in a top jurisdiction with the objective to support the world’s energy-transition goals. Alongside its exploration partner Denison, Foremost will be committed to a strategic and disciplined exploration strategy to identify resources by testing drill–ready targets with identified mineralization along strike of recent major discoveries. Foremost also maintains a secondary portfolio of significant lithium projects at different stages of development spanning over 50,000 acres across Manitoba and Quebec. For more information about the company, visit www.ForemostLithium.com

Foremost Lithium Resource & Technology Ltd. (FMST), closed Tuesday's trading session at $3.09, off by 1.5924%, on 20,138 volume. The average volume for the last 3 months is 45,475 and the stock's 52-week low/high is $1.77/$4.36.

The QualityStocks Company Corner

SenesTech Inc. (NASDAQ: SNES)

The QualityStocks Daily Newsletter would like to spotlight SenesTech Inc. (NASDAQ: SNES).

SenesTech (NASDAQ: SNES), the rodent fertility-control experts and inventors of the only EPA-registered contraceptive for male and female rats, will be spotlighted at the upcoming Lytham Partners Fall 2024 Investor Conference. Company officials are slated to participate in a webcast presentation during the event, which will be held Oct. 1, 2024; the company's presentation is scheduled to begin at 11 a.m. ET. In addition, SenesTech representatives will host online one-on-one meetings with investors during the virtual conference.

To view the presentation, visit https://ibn.fm/Ymozg

To view the full press release, visit https://ibn.fm/6R2Mr

SenesTech Inc. (NASDAQ: SNES) is the rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats. The company’s technology provides an innovative and humane method for managing rat populations.

SenesTech is focused on developing effective solutions that are grounded in science and proven through research, all while providing value to people, communities and the environment. The company’s passion is to create a healthier world by better controlling rat pest populations. This aim is critical, as, if left unchecked, a breeding pair of rats and their descendants can produce up to 15,000 pups after just one year.

The company strives for clean cities, efficient businesses and happy households – with a product that was scientifically designed to be effective without killing rats. SenesTech is committed to the sustainable, humane treatment of animals, improving the quality of all human life and enhancing environmental stewardship through the global application of its effective solution in fertility control technology.

SenesTech is headquartered in Phoenix, Arizona.

ContraPest®

SenesTech’s first product, ContraPest®, applies revolutionary technology to a global challenge that has persisted since the Middle Ages – the proliferation of rats in urban and agricultural settings. ContraPest® targets the reproductive capabilities of Norway and roof rats. As a highly palatable liquid, the formulation promotes sustained consumption, helping to reduce fertility in both male and female rats, bringing populations down and keeping them down.

The company’s flagship offering can be used as part of integrated pest management (IPM) programs – fitting seamlessly into all IPM programs – to help reduce reproduction and magnify the success of these protocols, or as a standalone solution for customers who want to reduce or eliminate the use of lethal rodent control methods.

In multiple, independent field deployments, ContraPest was shown to reduce rat activity over 90% when added to an existing IPM program.

ContraPest® is registered federally as a General Use Product.

Delivery Systems and New Products

In July 2023, SenesTech began to distribute a new delivery system for ContraPest®, the Isolate Bait System™. This new delivery system brings to market a simple design that enables more efficient deployment, incorporates an enhanced formulation of ContraPest® that is expected to provide improved performance of the fertility control bait in the field and is paired with a new bait station that is more space-efficient and economical.

The other delivery systems available for ContraPest include the Ultimate Bait System™, a tank and tray in a larger format for use with more severe infestations, and the Elevate Bait System™, a unique delivery system that targets above ground infestations, as with roof rats.

SenesTech, as of August 2023, is also in the final stages of releasing a soft bait formulation, which provides the unique attributes of proven fertility control in an industry-familiar format demanded by big box retailers, key e-commerce channels and leading industry pest management professionals.

Market Opportunity

According to SenesTech’s figures, rats cause over $27 billion in damage to public and private infrastructure annually in the United States. Rats also destroy 20% of the global stored food supply every year by consuming or contaminating it.

Rats are known to spread at least 35 diseases, globally posing a dangerous risk to public health and safety. Not only does this age-old problem persist despite extensive campaigns to eradicate it, but multiple sources have reported that post-COVID rat populations have boomed.

Poison-based control methods sicken rats, and they typically die slowly. An animal that eats a poisoned rat may also sicken or die. The global rodenticide market is projected to be worth $1.7 billion by 2026.

In one case study, results reported by the customer showed a $5,000 investment in ContraPest® saved more than $500,000 annually in reduced labor, loss and damage.

Management Team

Joel Fruendt is SenesTech’s President and CEO. He has 15 years of executive leadership in the vector and pest control industries as Vice President and General Manager of Clarke Environmental Inc., a leading vector and pest control products and services company. He has extensive expertise in the development and manufacturing of EPA-registered chemical control products, and the commercialization and sale of those products. He received the ‘Smart Leaders’ award from Smart Business Magazine and holds a bachelor’s degree in business from Illinois Wesleyan University.

Tom Chesterman is CFO at SenesTech. He has over 20 years of experience as the CFO of public companies in the life science, tech and telecommunications industries. Most recently, he was the Vice President and Treasurer of GCI, a telecommunications company. Previous to that, he was the CFO of life science companies Bio-Rad Laboratories, Aradigm and Bionovo. He has a bachelor’s degree from Harvard University and an MBA from the University of California at Davis.

Dan Palasky is Chief Technical Officer at SenesTech. Previously he held the title of Vice President of Research & Development at PLZ Corp., a manufacturer of chemical consumer products, serving as the technical expert for its entire product portfolio. He started his career with Camie-Campbell, Inc., as a chemist in the R&D department. Mr. Palasky received his bachelor’s degree in chemical engineering from the Missouri University of Science & Technology and his MBA in Project Management from Aspen University.

SenesTech Inc. (NASDAQ: SNES), closed Tuesday's trading session at $2.9, up 20.8333%, on 159,060 volume. The average volume for the last 3 months is 360,114 and the stock's 52-week low/high is $1.90/$78.00.

Recent News

Platinum Group Metals Ltd. (TSX: PTM) (NYSE American: PLG)

The QualityStocks Daily Newsletter would like to spotlight Platinum Group Metals Ltd. (TSX: PTM) (NYSE American: PLG).

New battery technologies are being researched and developed to rival lithium-ion batteries in terms of efficiency, cost and sustainability.

Lithium-sulfur batteries could offer advantages over lithium-ion batteries, including increased range and storage capacity.

Companies working in this space include Lion Battery Technologies Inc. founded by Platinum Group Metals Ltd. and Anglo American Platinum Limited.

The battery of choice these days, relied on to power everything from digital devices to electric vehicles and even energy-storage systems, is the lithium-ion battery. However, lithium-ion technology has its drawbacks; consequently, other battery solutions are being developed, including lithium sulfur. Through its subsidiary Lion Battery, Platinum Group Metals (NYSE American: PLG) (TSX: PTM) is working to strengthen its foothold in the lithium-sulfur space.

Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) is the operator of the Waterberg Project, a bulk underground platinum group metals (PGM) deposit discovered by Platinum Group in 2011 and located on the Northern Limb of the Bushveld Complex in South Africa. The Waterberg Project is planned as a fully mechanised platinum, palladium, rhodium and gold mine, including by-product copper and nickel production, and is projected to be one of the largest and lowest cost PGM mines globally.

The project is a joint venture between Platinum Group; integrated PGM producer Impala Platinum Holdings Ltd. (OTCQX: IMPUY); Japanese consortium HJ Platinum, which includes trading house Hanwa Co. and the government-backed Japan Organization for Metals and Energy Security (JOGMEC); and local empowerment partner Mnombo Wethu Consultants (Pty) Ltd. Platinum Group has an effective 50.22% interest in the Waterberg Project.

The company’s primary business objective is to advance the Waterberg Project to a development and construction decision. An update to the 2019 Definite Feasibility Study is expected in 2024.

PGMs are essential and precious metals that include platinum, palladium, rhodium, iridium, osmium and ruthenium. These metals are known for their purity, high melting points and unique catalytic properties. They are utilized in a number of industrial processes, technologies and commercial applications and play a critical role in autocatalysis and pollution control in the automotive sector. The bulk of global PGMs are mined in Southern Africa and Russia.

The unique properties of PGMs are being applied to various technologies as possible solutions for more efficient energy generation and storage, which may create new demand for PGMs. The company’s battery technology initiative through Lion Battery Technologies Inc., using platinum and palladium in lithium battery technologies, represents one such new opportunity in the high-profile lithium battery research and innovation field.

Platinum Group Metals Ltd. founded Lion Battery Technologies Inc. in partnership with Anglo American Platinum Ltd. (AMS: JNB) to support the use of palladium and platinum in lithium battery applications. Lion Battery has entered into an agreement with Florida International University to further advance a research program that uses platinum and palladium to unlock the potential of Lithium Sulfur (Li-S) battery chemistries.

Platinum Group is headquartered in Vancouver, B.C., and Johannesburg, South Africa.

Waterberg Project

Platinum Group’s sole material mineral property, the Waterberg Project, is presently in process with pre-construction permitting; engineering work, including road upgrade and traffic studies; finalization of power and water infrastructure design; and construction camp design.

The company’s principal product from the Waterberg Project is planned to be a PGM-bearing concentrate. The concentrate will contain economic amounts of six elements comprising platinum, palladium, rhodium, gold, copper and nickel. The company’s partner in the Waterberg Project, Impala Platinum Holdings, has acquired a right of first refusal to enter into an offtake agreement, on commercial arm’s-length terms, for the smelting and refining of mineral products from the Waterberg Project.

The Waterberg project has proven and estimated reserves of 19.5 million ounces of PGMs and gold. When fully operational, the mine is projected to produce more than 400,000 ounces of PGMs annually during the peak period of steady state production. The life of the mine is projected at 45 years.

South Africa’s PGM mining sector remains closely tied to economic developments in the global automotive industry, which in 2022 accounted for approximately 43% of the total global demand for platinum and 82% of the total global demand for palladium.

Market Opportunity

According to a report from Straits Research, a global market and business research firm, the worldwide platinum market had an estimated value of $7.72 billion in 2022 and is projected to reach $11.95 billion by 2031. That represents a CAGR of 5.13% over the forecast period.

Platinum, one of the rarest of precious metals, is about 30 times scarcer than gold. It is crucial to the automotive and electronics industries and is also used to make jewelry. Stricter emissions regulations around the world have led to an increased demand for platinum to be used in catalytic converters to reduce automotive emission, the report states.

A report from Allied Market Research estimated the global palladium market at $16.3 billion in 2021 and projects the market will reach $28.6 billion by 2031, growing at a CAGR of 5.8% over the period.

Palladium is also used in automotive catalytic converters for reducing emissions and in jewelry, dentistry, watchmaking, blood sugar test strips, aircraft spark plugs, surgical instruments, electrical contacts and musical instruments.

An increase in demand for consumer electronics has driven demand for palladium-based multilayer ceramic capacitors (MLCC) used to store energy in electronic devices such as broadcasting equipment, mobile telephones, computers, electronic lighting and high voltage circuits, according to the report.

Management Team

Frank R. Hallam is Co-Founder, Director, President and CEO of Platinum Group. He has over 30 years of experience in the mining, minerals and petroleum industry as an operator, principal and founder. He was a co-founder and former CFO of MAG Silver Corp. He was also co-founder and director of West Timmins Mining Inc. and a director of Lake Shore Gold Corp. In addition, he was CFO and director with gold exploration company Tan Range Exploration Corp. He is a Chartered Professional Accountant and was formerly an auditor in the public mining practice of PwC. He holds a Bachelor of Business Administration from Simon Fraser University.

Greg Blair is CFO of Platinum Group. He has been with Platinum Group since 2010 in various roles, most recently as Interim CFO. Prior to joining Platinum Group, he was at a public accounting firm working on public company (mainly mining) audits. He is a Chartered Professional Accountant and holds a degree in Economics from Simon Fraser University and has completed the Canadian Securities Course.

Kris Begic is VP Corporate Development of Platinum Group. He has over 25 years of experience in the mining industry and capital markets and has been involved with the raising of over $500 million for various exploration and development projects globally. His efforts are focused on project generation, mergers and acquisitions, capital markets, investor relations and marketing.

Platinum Group Metals Ltd. (NYSE American: PLG), closed Tuesday's trading session at $1.47, up 12.2137%, on 402,352 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $78.00/$.

Recent News

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

Hemp advocates in the state of California may sue the governor over the recently proposed emergency rules because they may negatively impact vulnerable individuals. During a press conference held earlier this month, Governor Gavin Newsom announced that he would be clamping down on intoxicating hemp products that were often marketed to minors. The governor explained that because drug peddlers are targeting children with unregulated and dangerous hemp products containing THC, it was important to increase enforcement to prevent minors from accessing these products, while also closing loopholes. Newsom proposed these regulations after AB 2223, which targeted hemp, failed to get approved in the Senate. Newsom signaled that the rules would take effect as soon as the Office of Administrative Law approved them. Public comment on the proposed rules ended on Sept. 18, 2024. An ideal path for the hemp industry and companies that make CBD products, such as Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ), would be for the federal government to pass comprehensive regulations for cannabinoids so that states can derive their own iterations from these clear rules.

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.

Production

MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Tuesday's trading session at $0.015, up 42.8571%, on 4,002 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.000001/$0.09.

Recent News

Horizon Fintex | Upstream

The QualityStocks Daily Newsletter would like to spotlight Horizon Fintex | Upstream

As the world of Web3 gaming keeps evolving, it is becoming clear that Pixels, the blockchain-based farm simulator, is at the forefront in more ways than one. With more than a million daily active users, Pixels has officially become the largest Web3 game out there since its launch in 2021. But this is not all — the game has made a bold move: clickable in-game ads, which are already generating impressive results. On July 24, 2024, Pixels launched its first intrinsic in-game advertising feature, strategically placing ads on virtual billboards and banners. Picture this: Take a stroll through your virtual land, casually spotting a clickable ad for a crypto token. More than 50 out of the 237 people who clicked the ad made a purchase. That's a conversion rate of more than 20% in only two weeks! That's a win-win for both gamers and advertisers. Despite the risks, Pixels' ad strategy isn't only benefiting advertisers. The players, especially those who own virtual land, are raking in some sweet rewards too. Thanks to in-game ads, landowners are earning revenue from billboards placed on their digital plots, and some are reportedly seeing returns of up to 33% annual yield on their NFTs, according to Quinn Campbell, founder of ad tech company PTAL. In-game adverts could find some utility among enterprises such as Horizon Fintex as they drum up awareness about their different solutions needed by the public.

Horizon Fintex is a software business specializing in compliant securities solutions. The company aims to facilitate the future of capital markets by leveraging the regulatory experience of Wall Street bankers and the proven track record of technology veterans to bring focus to compliance, efficiency, security and transparency.

Horizon’s flagship product is the revolutionary trading app ‘Upstream’, a MERJ Exchange Market, and the first regulated market powered by a blockchain to offer both digital securities and NFT trading. Upstream traders experience T+0 settlement, best bids and offers displayed on a transparent public orderbook that prevents predatory market practices – all from a user-friendly trading app.

Products

Horizon Fintex offers a full suite of end-to-end blockchain-enhanced software solutions to create a seamless experience for both issuers and investors. Its product suite includes:

  • Securitization & IssuanceETSware is an end-to-end Electronic Trading System streamlining capital raising from primary issuance through compliant secondary trading.
  • KYC Compliance OnboardingKYCware is a white label Know Your Customer (KYC) and Anti-Money Laundering (AML) compliance software solution offering best-in-class cryptographic security to compliantly onboard and verify user identity through a smartphone application.
  • AML Screening SoftwareAMLCop offers advanced Anti-Money Laundering (AML) software to streamline the verification of user details against a proprietary database of global sanctions, politically exposed persons (PEPs) and watchlists.
  • Cap. Table Management ToolsCustodyWare equips registered U.S. transfer agents with next-generation cap. table management software to manage securities on behalf of their clients pursuant to an SEC-registered or exempt securities offering.
  • Exchange & Trading App TechnologyOpen Order Book offers Ethereum blockchain securities exchange software to power the next generation of trading venues for digital assets.

Upstream – The Horizon-Powered Trading App

Upstream is a joint venture with MERJ Exchange (merj.exchange), an affiliate of the World Federation of Exchanges.

Upstream aims to be the premiere global trading hub offering issuers around the world exposure to a digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD (fiat) to increase liquidity and enhance price discovery; while also offering investors access to dual-listed companies, IPOs, crowdfunded companies, U.S. & Int’l. equities, digital coupons and NFTs directly from a user-friendly trading app.

Upstream aims to unlock liquidity for investors of all levels while offering industry-leading levels of transparency, accessibility and investor protections enforced using Ethereum blockchain technology.

Management Team

Brian Collins is the CEO of Horizon Fintex. He founded the company in 2010. From 1999-2010, Mr. Collins was CEO of Abbey Technology in Switzerland, specializing in the design of trading software for Swiss banks. Prior to this, he worked for Credit Suisse in Zürich, designing and building proprietary equity trading solutions. Mr. Collins graduated in 1990 with a BS in Computer Systems from the University of Limerick, Ireland.

Mark Elenowitz is the company’s President. He is a Wall Street veteran with over 29 years of experience. Mr. Elenowitz was the co-founder of a U.S. broker dealer and is Managing Director of two U.S. broker dealers, responsible for advising clients on compliance, capital structure and capital market navigation. He was responsible for leading the first successful Reg A+ IPO of a company to list on the NYSE and others which listed directly onto Nasdaq. He is a noted speaker at Small Cap and Reg A events, including the SEC Small Business Forum, and has been profiled in BusinessWeek and CNBC, as well as several other publications. Mr. Elenowitz is a graduate of the University of Maryland School of Business and Management with a BS in Finance and holds Series 24, 62, 63, 79, 82 and 99 licenses.

Dr. Andrew Le Gear is the CTO of Horizon Fintex. Prior to joining the company in 2013, he worked as a software engineer with Dell Inc. (2012-2013) and Lehman Brothers and Nomura Plc. (2007-2012). Dr. Le Gear was a co-founder of Juneberi Ltd., a research-driven software tech start-up (2004-2007). He graduated in 2006 with a Ph.D. in Computer Science from the University of Limerick, Ireland.

Peter Hall is the company’s CIO. Prior to joining Horizon Fintex in 2011, he worked at Microsoft (2008-2011), Atos Origin (2004-2008) and AIT Group Plc. (1998-2002). Mr. Hall has held CISSP certification since 2010. He graduated from the University of Sheffield, UK in 1995 and earned an MS from the University College London in 2006.

Mike Boswell is the CFO of Horizon Fintex. A Wall Street veteran, he co-founded a U.S. broker dealer and served as Chief Compliance Officer. Mr. Boswell was also Managing Director of TriPoint Capital Advisors, a merchant banking and financial consulting company, and CFO of Mission Solutions Group, a privately held defense sector firm. He earned an MBA from John Hopkins University and a BS in Mechanical Engineering from the University of Maryland. Mr. Boswell holds Series 24, 62, 63, 79, 82 and 99 licenses.

Recent News

chart

Nutriband Inc. (NASDAQ: NTRB)

The QualityStocks Daily Newsletter would like to spotlightFathom Nutriband Inc. (NASDAQ: NTRB) .

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is announcing that its patent application, which protects its AVERSA(TM) abuse deterrent transdermal technology, has been allowed in China. This follows the receipt of a Notice of Allowance from the Chinese National Intellectual Property Administration ("CNIPA") for the application entitled "Abuse and Misuse Deterrent Transdermal Systems." The latest allowance expands the company's international intellectual property portfolio, which now includes patents issued in 46 countries: Australia, Canada, China, Europe, Japan, Korea, Mexico, Russia, the U.S., and more.

To view the full press release, visit https://ibn.fm/oxL2p

Nutriband Inc. (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA™ technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids.

AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico and Australia.

The company’s business model is to apply its transdermal technology to existing FDA-approved drugs with a goal of improving safety, efficacy and patient comfort while qualifying for a limited-development regulatory pathway that reduces the number of clinical trials required for approval of new drugs.

Nutriband has three subsidiaries, including 4P Therapeutics, its clinical and regulatory subsidiary; Pocono Pharmaceutical, a contract manufacturer for a wide range of clients; and Active Intelligence, a developer of sports recovery products. This ownership of manufacturing and clinical development capabilities drastically reduces costs for AVERSA and other technologies.

In April 2024, Nutriband announced that the company had been engaged by and received a first order from Fit For Life Group, a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband’s wholly owned Active Intelligence subsidiary will act as manufacturer.

The company is headquartered in Orlando, Florida.

Products

Nutriband’s lead product candidate is AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal patch. The company announced in March 2024 that it will submit a New Drug Application to the U.S. Food and Drug Administration seeking approval to market AVERSA Fentanyl.

Nutriband has partnered with Kindeva Drug Delivery, a leading global contract development and manufacturing organization, to incorporate Nutriband’s AVERSA abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. Because Nutriband’s abuse-deterrent technology is incorporated into the fentanyl patch but is physically separate from and does not come in contact with the drug layer, the clinical trials typically needed to demonstrate safety and efficacy for a new drug formulation would not be required.

AVERSA Fentanyl has the potential to be the first and only abuse deterrent patch approved anywhere in the world. The company plans to seek an expedited review by the FDA, as has been granted for certain abuse-deterrent oral opioid products, which shortens the regulatory review period to six months from the conventional 10-month FDA review cycle for NDAs.

Nutriband’s AVERSA product development pipeline also includes abuse deterrent versions of currently approved and marketed transdermal patches containing buprenorphine, an opioid used to treat opioid use disorder, and methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD). Both are labeled with FDA-required warnings for the risk of abuse and misuse, as well as warnings against accidental exposure.

Market Opportunity

Nutriband cites a market analysis report from Boston-based Health Advances, a healthcare and life sciences consulting firm. According to the report, upon FDA approval, AVERSA Fentanyl has the potential to reach peak annual sales of $200 million in the U.S.

The company further states that, should non-abuse-deterrent transdermal fentanyl products lose FDA marketing approval, AVERSA Fentanyl would have greater pricing flexibility and would have the potential to generate more than $500 million in annual revenue.

Management Team

Gareth Sheridan is Co-Founder and CEO of Nutriband. He was Ireland’s ‘Young Entrepreneur of the Year’ in 2014 for establishing Nutriband. He has worked as a Business Mentor with 100 Minds, a social enterprise that brings together some of Ireland’s top college students and connects them with a cause to achieve large charitable goals. He received a B.Sc. in Business and Management from Dublin Institute of Technology.

Serguei Melnik is Co-Founder and President of Nutriband. He has been involved in general business consulting for companies in the U.S. financial markets and setting up legal and financial frameworks for operations of foreign companies in the U.S. He previously was the COO of Florida-based Asconi Corporation. He also was a lawyer in the Department of Foreign Affairs, JSC Bank “Inteprinzbanca,” in Chisinau, Moldova, and prior to that practiced law in Moldova. He is fluent in four languages.

Jeff Patrick, Pharm.D., is Chief Scientific Officer of Nutriband. He currently serves as Director of the Drug Development Institute at the Ohio State University Comprehensive Cancer Center. His prior roles included Global Vice President at Mallinckrodt Pharmaceuticals Inc.; and roles at Dyax, Myogen/Gilead, Actelion and Sanofi-Synthelabo Inc. He was a clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy.

Gerald Goodman is CFO of Nutriband. He is a certified public accountant with his own firm, Gerald Goodman CPA. He also practiced with Madsen & Associates, CPAs, and was a partner in the accounting firm of Wiener, Goodman & Company. He is also a director of Lifestyle Medical Network Inc., which provides management services to healthcare providers. He is a graduate of Pennsylvania State University, where he received a bachelor’s degree in accounting.

Nutriband Inc. (NASDAQ: NTRB), closed Tuesday's trading session at $6.7, off by 0.297619%, on 75,544 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.53/$9.595.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, today shared a video update to shareholders provided by CEO and Chairman David Michery. In the video, Michery provides a detailed overview of the company's recent progress, including sales and distribution expansion and financial performance. According to the update, the company's sales activities with existing and new companies have resulted in new sales opportunities and vehicle orders received and or completed. Additionally, Mullen has secured financing to support sales growth through a $100 million preferred instrument and a $150 million fully available equity line. The update also highlighted Bollinger Motors' progress, including regulatory and sales approvals, its partnership with Roush Industries, and the commencement of production on the first customer-ready B4 electric trucks.

"Our group of companies, including Bollinger Motors and Mullen Advanced Energy Operations, continue to work towards meeting milestones and growing sales and I remain optimistic that the company success will continue despite the challenges associated with our stock price," commented Michery.

To view the video update, visit https://ibn.fm/3ywdM

To view the full press release, visit https://ibn.fm/wTgwe

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $5.07, off by 13.4812%, on 2,235,400 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.9001/$5700.00.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

The company is seeking an accelerated approval regulatory pathway for CNM-Au8® for ALS.

The FDA agreed to an in-person meeting to reevaluate Clene's submission.

Lead drug candidate CNM-Au8 has been shown to restore and protect neurological function, offering hope for patients with neurodegenerative conditions.

The FDA meeting will be held before the end of November and will be attended by top FDA officials and key opinion leaders in ALS, biostatistics and biomarkers.

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis ("ALS") and multiple sclerosis ("MS"), announced an upcoming meeting with the U.S. Food and Drug Administration ("FDA") leadership to discuss lead candidate CNM-Au8®.

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Tuesday's trading session at $4.41, off by 1.5625%, on 46,027 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.8181/$13.20.

Recent News

SuperCom Ltd. (NASDAQ: SPCB)

The QualityStocks Daily Newsletter would like to spotlight SuperCom Ltd. (NASDAQ: SPCB) .

SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-government, Internet of Things ("IoT") and cybersecurity sectors, has secured a three-year national contract with the government of a European country. The contract calls for SuperCom deploy its PureSecurity domestic violence ("DV") monitoring solution. Since entering the market, SuperCom has become a leader in Europe's national domestic violence monitoring sector, deploying a substantial number of units and outpacing its competitors. This new contract further solidifies the company's continued expansion in the region as it works to enhancing domestic violence prevention and intervention capabilities.

"We are honored to collaborate with this EU country to support their initiatives in addressing domestic violence through advanced monitoring solutions," said SuperCom president and CEO Ordan Trabelsi in the press release. "Winning our fifth national domestic violence contract in Europe is a testament to the trust governments place in our technology and our commitment to enhancing public safety. Our DV monitoring solution offers real-time tracking, communication and security, providing authorities with a powerful tool to improve the protection of vulnerable individuals and promote offender accountability."

To view the full press release, visit https://ibn.fm/axedM

SuperCom Ltd. (NASDAQ: SPCB) provides secured solutions for the e-government, IoT and cybersecurity sectors. Since 1988, the company has been a trusted global provider of traditional and digital identity offerings, providing cutting-edge electronic and digital security solutions to governments and organizations, both private and public, around the world.

SuperCom’s mission is to revolutionize the public safety sector worldwide through proprietary electronic monitoring technology, data intelligence, and complementary services.

The company is headquartered in Tel Aviv, Israel, with offices in California and other regions in the U.S.

Business Units

IoT and Connectivity

SuperCom IoT products and solutions provide advanced electronic monitoring solutions and services to criminal justice agencies, enabling customers to detect unauthorized movement of people, vehicles, and other monitored objects. The company provides an all-in-one, field-proven PureSecurity offender monitoring suite, accompanied by services such as GPS monitoring, home detention, domestic violence prevention, and more. The company’s services are specifically tailored to meet each client’s needs.

SuperCom’s proprietary Puresecurity suite of hardware, connectivity, and software components is the foundation for its criminal justice services and offerings. SuperCom is leveraging its extensive technology expertise to implement groundbreaking artificial intelligence (AI) technologies into various parts of its core offerings. By leveraging the power of AI, SuperCom’s PureSecurity platform can offer new abilities, such as amplified data analysis, predictive modeling, and streamlined automation – all geared toward optimizing decision-making and operational efficiency.

Competitive advantages of SuperCom’s technology include:

  • Long Battery Life (No Tag Charging Required)
  • Ultra Lightweight Form Factor
  • Next-Gen Location Tech
  • Protection of Domestic Violence Victims
  • And More

 

Cybersecurity

In 2015, SuperCom identified the cybersecurity market as a fast-growing space with significant advantages due to synergistic technologies and a shared customer base with its e-Gov and IoT business units. Consequently, SuperCom strategically acquired Prevision Ltd., a company with a strong presence in the market and a broad range of competitive cybersecurity services.

During the first quarter of 2016, SuperCom acquired Safend Ltd., an international provider of cutting-edge endpoint data protection guarding against corporate data loss and theft through content discovery and inspection, encryption methodologies, and comprehensive device and port control.

Both acquisitions significantly expanded the breadth of the company’s global cybersecurity capabilities.

e-Gov

Through proprietary e-government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has helped governments, and national agencies design and issue secured multi-identification, or Multi-ID, documents and robust digital identity solutions to their citizens, visitors, and lands.

The company has focused on expanding its activities in the traditional identification, or ID, and electronic identification, or e-Gov, markets, including the design, development, and marketing of identification technologies and solutions to governments in Europe, Asia, America, and Africa using SuperCom’s e-Government platforms.

Market Opportunity

Data from Berg Insight estimates the market for electronic monitoring solutions will grow from $1.2 billion in 2021 to $2.1 billion in 2026, marking a CAGR of 10.8% for the forecast period.

High recidivism rates, prison overcrowding, and soaring incarceration costs are some factors that are driving the electronic monitoring of offenders’ market growth.

An analysis by ReportLinker forecasts that the global cybersecurity market will grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, achieving a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving the cybersecurity market growth.

Management Team

Ordan Trabelsi is President and CEO of SuperCom. He has over 15 years of experience as CEO, growing high-tech companies globally. He also has experience in research and development and product innovation, as well as hands-on experience in cybersecurity, encryption, advanced mathematics, and mobile and internet network technologies. Prior to joining SuperCom, he served as co-founder and CEO of Klikot Inc., a global social networking company. He holds an MBA from Columbia University and a B.Sc. in Computer Engineering from The Technion: Israel Institute of Technology.

Barak Trabelsi is COO of SuperCom. He has expertise in big data, cyber, mobile, and internet network technologies, as well as extensive experience in product development and strategies. Prior to joining SuperCom, he served as Senior Product Manager at Equinox Ltd. Before that, he served for four years as VP of R&D at Sigma Wave, a wireless, security, and internet-focused company. He holds a B.Sc. in Computer Science and Business, as well as an MBA from Tel Aviv University.

Gil Alfi is VP of Sales at Safend Ltd., SuperCom’s cybersecurity subsidiary. He joined SuperCom in 2016 as VP of Business Development for Safend. He has more than 18 years of experience in technology companies. He served as an R&D team technology lead for more than seven years and as Director of Product Management for various telecom and wireless companies for more than 10 years. Prior to joining SuperCom, he served as Regional Sales Director at Safend, managing sales regions in Europe and Africa. He holds a B.Sc. in Computer Science and Mathematics and an M.Sc. in Computer Science from Bar-Ilan University.

SuperCom Ltd. (NASDAQ: SPCB), closed Tuesday's trading session at $3.75, off by 1.1962%, on 95,329 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.55/$22.60.

Recent News

FingerMotion Inc. (NASDAQ: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (NASDAQ: FNGR) .

Payment network Affirm recently announced that it is integrating with Apple Pay to expand Apple Pay's payment options. Apple Pay users on both iPad and iPhone can now make scheduled payments, thanks to Affirm's integration. Furthermore, the payment network can break down qualifying purchases into either biweekly or monthly payments with rates as low as 0% APR. iPadOS 18 and iOS 18 users with Apple Pay will be able to make payments over time via Apple Pay's Other Cards & Pay Later Options when they check out. Once they select Affirm, Apple Pay users will be subject to a quick eligibility check that will not impact their credit score. After they receive approval, the users will have access to various payment plans and can use touch ID or face ID to complete their choices. These services also  allow consumers to budget their finances and make large purchases that would have required months or even years of saving, without going into debt or experiencing major financial strain. Such services are especially popular with younger buyers who are more likely to seek alternatives to conventional loans and credit cards. Apple Pay's integration of Affirm highlights a growing trend of tech companies teaming up with BNPL providers and points to the convergence of new payment solutions and mobile money solutions such as Apple Pay. As mobile payments continue to evolve, we are likely to see other emerging players such as FingerMotion Inc. (NASDAQ: FNGR) gaining traction in the different markets where they have interests.

FingerMotion Inc. (NASDAQ: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Tuesday's trading session at $2.09, off by 1.8779%, on 97,070 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.63/$7.37.

Recent News

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT) .

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, has appointed a new chief artificial intelligence ("AI") scientist: Lance Myers, PhD. According to the announcement, Myers is the former head of data science at Verily, formerly Google Life Sciences. A renowned industry leader and pioneer in digital health data analytics and body-worn biosensor technologies, Myers is a globally respected authority on utilizing AI in biosensor tech. In his new position, Myers will drive innovation and strategic growth for HeartBeam as the company looks to fully leverage its AI capabilities.

"We've made tremendous progress with our deep learning approach with data demonstrating that combining HeartBeam AI with a vector-based approach delivered equivalent performance to a 12-lead ECG and greatly improved detection of atrial flutter over a single-lead ECG," said HeartBeam CEI and founder Branislav Vajdic, PhD, in the press release. "As we enter the next phase of development, we're pleased to have an industry leader of Lance's caliber join our team. His insights and expertise will have an immediate impact as we strive to transform cardiac care by harnessing the power of AI with our data-rich technology."

To view the full press release, visit https://ibn.fm/LSGsD

HeartBeam Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector 12-lead electrocardiogram (ECG) platform for heart attack detection anytime, anywhere. The company’s proprietary ECG telehealth technology aims to redefine the way high risk cardiovascular patients are diagnosed in ambulatory and acute care settings. HeartBeam’s initial focus is on providing diagnostic data to help physicians with care management of patients with cardiovascular disease.

In August 2022, HeartBeam announced that it submitted its HeartBeam AIMI™ software for approval from the U.S. Food and Drug Administration (FDA). HeartBeam AIMI is a platform technology to improve the speed and accuracy of heart attack detection in acute care settings. The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023.

HeartBeam sees submission of its first product based on its platform technology as an important milestone toward commercialization, which underscores the company’s continued progress toward making the HeartBeam AIMI platform widely available to help emergency department physicians quickly and accurately identify a heart attack.

While the FDA conducts its regulatory review, HeartBeam will focus on executing key components of its commercialization plan and subscription revenue model. It will also continue to engage in discussions with strategic institutions, including academic centers, regional healthcare systems and regional community hospital systems that can utilize HeartBeam products.

The company is based in Santa Clara, California.

Products

HeartBeam’s development portfolio includes two products:

  • HeartBeam AIMI is software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack in acute care settings and, as noted above, has been submitted for FDA approval; and
  • HeartBeam AIMIGo™, the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system for remote heart attack detection.

HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause. While approximately 82% of chest pain ED visits are unnecessary, patients delay approximately 3 to 4 hours after symptoms begin, increasing mortality rates by 40%. The company’s goal is to shorten the time to treatment outside of the medical facility to improve patients’ well-being.

HeartBeam’s AIMIGo is a powerful, portable and easy-to-use prescription-based product. It comprises a smartphone app, a credit card-sized ECG device placed on a patient’s chest, the HeartBeam cloud platform, and a digital portal for the physician to view ECG results and direct patient action. For the first time outside of a medical setting, HeartBeam AIMIGo enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if needed.

Pending FDA clearance, AIMIGo is initially intended to be available by prescription, and is reimbursable under existing remote patient monitoring codes (RPM codes). This provides a new revenue stream to physicians who before did not have a way to monitor these high-risk patients. The RPM codes provide a monthly reoccurring revenue stream to the company, as well. On average, at current reimbursement rates, the practice will receive $1,300+ per year per patient they monitor, and the company will receive $600 per year per patient from this RPM reimbursement.

Market Overview

Adoption rates of telehealth services increased dramatically in recent years, with the COVID-19 pandemic serving as a major driver of growth. Among the areas seeing the greatest expansion are cardiology, radiology, behavioral health and online consultation.

Encouraging this growth, governments are actively developing new policies and reimbursement guidelines to promote the use of digital health platforms. The U.S. Centers for Medicare & Medicaid Services (CMS), for example, has recently expanded reimbursement for telehealth services. U.S. market growth is also being driven by the rising prevalence of chronic conditions and the growing geriatric population.

Remote heart attack detection is a previously unsolved problem with a massive and underserved market that is several times larger than the $2 billion total addressable market (TAM) in the U.S. for ECG cardiac arrhythmia monitoring.

Approximately 8 million Americans have suffered at least one heart attack, and a total of 18 million have been diagnosed with coronary artery disease (CAD). Based on these figures, HeartBeam projects a total addressable U.S. market TAM valued at $10 billion annually for its AIMIGo solution for remote heart attack monitoring of CAD.

Management Team

Branislav Vajdic, Ph.D., Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam’s technology to fit his vision for the company. Prior to HeartBeam, from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space. From 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management position. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices, as well as chip design. Dr. Vajdic holds a Ph.D. in Electrical Engineering from the University of Minnesota.

Jon Hunt, Ph.D., has over 35 years’ experience in the medical/medical device industry with extensive domestic and international experience in general management, clinical/regulatory, sales and marketing. He also has diverse experience in Fortune 500 companies, as well as start-up environments. Dr. Hunt was the Vice President of Clinical Science and Technology, Medical Device Innovation Consortium, from July 2019 to July 2021, and Vice President of Clinical and Regulatory Affairs, Cryterion Medical from January 2018 to June 2019 (acquired by Boston Scientific Corporation in July 2018 for $202M). Dr. Hunt was the Founding President and CEO of Bardy Diagnostics, Inc. from October 2013 to November 2017 (acquired by Hill-Rom Holdings, Inc.). Prior to joining Bardy Diagnostics, Dr. Hunt spent the previous 11 years as the Vice President of Clinical & Regulatory Affairs with Cameron Health, Inc. (acquired by Boston Scientific Corporation). Dr. Hunt spent the previous 10 years with Cardiac Pacemakers, Inc., St. Jude Medical and Cardiac Pathways Corporation. Dr. Hunt began his career with Cardiac Pacemakers, Inc. (now Boston Scientific Corporation) as the Director of Clinical Programs. He subsequently held positions at St. Jude Medical in Clinical Affairs and as the Business Unit Director for the Cardiac Rhythm Management division for Europe, the Middle East and Africa. At Cardiac Pathways Corporation, Dr. Hunt held various executive positions as Vice President of International Sales and Marketing and Vice President of Worldwide Sales and Marketing (acquired by Boston Scientific Corporation). Dr. Hunt received his Ph.D. in Motor Control from The Pennsylvania State University, his Master’s from California State University, Long Beach and his undergraduate degree from Keele University in the United Kingdom.

Rick Brounstein, HeartBeam’s Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017, Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. From 2008 to 2011, Mr. Brounstein was Chief Financial Officer of NewCardio, Inc., a microcap public company in the cardiology space, and, over his career, he has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007, Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. In January 2007, Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005, Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.

Ken Persen, HeartBeam’s Chief Technology Officer, combines over 28 years of experience in the medical device and digital health industries in engineering and senior management positions. Mr. Persen has been involved in several companies in Cardiac Rhythm Management, holding positions including Chief Executive Officer, Chief Technology Officer, Executive Vice President and Director of Engineering. Since 2016 and prior to joining HeartBeam, Mr. Persen was the Chief Technology Officer at LIVMOR, Inc., a digital health company. In addition, from 2016 through November 2021, he was also Chief Executive Officer of LIVMOR. Prior roles included Director of Engineering at Cameron Health (acquired by Boston Scientific), a late-stage medical device start up, and engineering and management positions at Guidant Corp. (acquired by Boston Scientific), a large medical device manufacturer. He has an undergraduate degree from University of Minnesota, Duluth, with a BA in Computer Science.

HeartBeam Inc. (NASDAQ: BEAT), closed Tuesday's trading session at $2.03, off by 0.4901961%, on 106,902 volume. The average volume for the last 3 months is 72,266 and the stock's 52-week low/high is $1.06/$3.3893.

Recent News

Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF)

The QualityStocks Daily Newsletter would like to spotlightFathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF).

Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) is a Canadian natural resource development and exploration company that targets high-grade nickel sulfide discoveries for use in the rapidly growing global electric vehicle (EV) market. The company has a portfolio of two high-quality exploration projects located in the prolific Trans Hudson Corridor in Saskatchewan.

Led by a management team with more than 100 years of combined mining and exploration experience, Fathom believes in a continuing bright outlook for nickel and its increasing use in the manufacturing of batteries needed for energy storage in the high-growth renewable energy and EV industries. The company’s modern approach to exploration has yielded significant new nickel discoveries.

Fathom is headquartered in Calgary, Alberta.

Projects

The Albert Lake Project

The Albert Lake Project comprises 90,460 hectares of lands located in north-central Saskatchewan, with over 80,000 hectares currently unexplored. The project is host to the historic Rottenstone Mine, a high-grade, open pit nickel sulfide past producer that was active from 1965 to 1969 and yielded ~26,000 tonnes of 3.3% Ni, 1.8% Cu, and >9 g/t Pd-Pt+Au.

The geological setting of the Albert Lake Project is within the Trans Hudson Orogeny (Corridor), which is host to numerous world-class nickel mining camps including the Thompson Nickel Belt (currently operating with more than 5 billion pounds of nickel produced since 1959), Lynn Lake (past producer) and Raglan Nickel Belt (currently operating with more than 39,000 tons of nickel produced in 2020).

The project is fully permitted. Exploration plans for 2024 include drilling a high-priority target located approximately 2km south of the historic Rottenstone Mine along with drilling other high-priority targets. Additional soil geochemistry, surface geophysical programs and geological mapping and prospecting will be performed during the summer field season.

The Gochager Lake Project

The Gochager Lake Project in northern Saskatchewan, also in the prolific Trans Hudson Corridor, was recently expanded through the addition of the contiguous Watt’s Lake property and direct staking, bringing its total land area to 22,620 hectares.

The Gochager Lake property is host to a historic resource defined by drilling in 1966-1967 consisting of 4.2 M tons grading 0.29% Ni and 0.08% Cu. Recent drilling by Fathom has defined multiple very robust off-hole borehole electromagnetic (BHEM) responses in eight of nine holes drilled in 2023 and three historic drill holes probed. There is very strong evidence of multiple, high-grade nickel-copper-cobalt steeply oriented chutes within the historic Gochager Lake Deposit.

Prior to Fathom exploration in 2023 and since 1970, exploration at the property has been limited to small drill programs in 1989-1990 and 2018. Exploration plans for 2024 include expanded surface geophysical programs, drilling and continued BHEM surveys to expand tons and increase the grade of the historic Gochager Lake deposit. Summer exploration will consist of soil geochemistry, mapping, prospecting and additional surface geophysical programs focused on identifying other Gochager-like deposits within the current land package.

Market Opportunity

Nickel plays a crucial role in clean energy technologies, and that is expected to cause demand to well outstrip supply for the foreseeable future.

With an annual market value of around $35 billion, nickel demand is projected to rise due to its intensive use in lithium-ion batteries used to power EVs. However, new discoveries of nickel sulfide deposits (currently the most reliable source for battery-grade class 1 nickel) have been rare, which could constrain class 1 nickel supply in the coming years.

According to Deloitte’s global EV forecast, total EV sales will grow from 2.5 million in 2020 to 11.2 million in 2025, reaching 31.1 million by 2030 and representing approximately 32% of the total market share for new car sales. Over the next 10 years, the EV market is projected to see a CAGR of 29%, with increased demand for nickel expected to be comparable.

Management Team

Fathom Nickel has assembled a best-in-class leadership team consisting of highly qualified industry professionals with deep knowledge and understanding of the mineral exploration industry and capital markets.

Ian Fraser, P.Geo., is CEO, VP Exploration and Co-Founder of Fathom Nickel. He has more than 35 years of experience in mineral exploration, as well as managing and implementing exploration projects in Canada and internationally. His experience includes resource interpretation and development of the Casa Berardi Gold Mine and Komis Gold Mine, as well as the Cisneros Gold Mine in Colombia.

Doug Porter, CPA, CA, CBV, is President, CFO and Director of Fathom Nickel. He is a senior financial and accounting executive with specific emphasis in resource company management. His career includes positions with Elan Coal Ltd., Altitude Resources Ltd. and StimWrx Oilfield Services Ltd.

Fathom Nickel Inc. (OTCQB: FNICF), closed Tuesday's trading session at $0.03105, up 21.2891%, on 592,100 volume. The average volume for the last 3 months is 116,397 and the stock's 52-week low/high is $0.013465/$0.1963.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $0.143, up 2.1429%, on 557,399 volume. The average volume for the last 3 months is 5.562M and the stock's 52-week low/high is $0.0955/$6875.00.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.